initial public offerings (IPOs) trading on American exchanges

Thursday, June 25, 2015

Catabasis Pharmaceuticals (CATB) began trading on the Nasdaq on Thur 25 June 2015

Catabasis Pharmaceuticals (CATB) today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $12.00 per share, before the underwriting discount, including 750,000 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Catabasis. The shares began trading on the NASDAQ Global Market on June 25, 2015.

About Catabasis

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. Catabasis's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. Catabasis’s focus is on treatments for rare diseases. Catabasis is also developing other product candidates for the treatment of serious lipid disorders.

No comments:

Post a Comment